|
1
|
American Thyroid Association Guidelines
Task Force; Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib
H, Moley JF, Pacini F and Ringel MD: Medullary thyroid cancer:
Management guidelines of the American thyroid association. Thyroid.
19:565–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nosé V: Familial thyroid cancer: A review.
Mod Pathol. 24(Suppl 2): S19–S33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moura MM, Cavaco BM, Pinto AE and Leite V:
High prevalence of RAS mutations in RET-negative sporadic medullary
thyroid carcinomas. J Clin Endocrinol Metab. 96:E863–E868. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ciampi R, Mian C, Fugazzola L, Cosci B,
Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, et
al: Evidence of a low prevalence of RAS mutations in a large
medullary thyroid cancer series. Thyroid. 23:50–57. 2013.
View Article : Google Scholar
|
|
5
|
Agrawal N, Jiao Y, Sausen M, Leary R,
Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, et al:
Exomic sequencing of medullary thyroid cancer reveals dominant and
mutually exclusive oncogenic mutations in RET and RAS. J Clin
Endocrinol Metab. 98:E364–E369. 2013. View Article : Google Scholar :
|
|
6
|
Tamburrino A, Molinolo AA, Salerno P,
Chernock RD, Raffeld M, Xi L, Gutkind JS, Moley JF, Wells SA Jr and
Santoro M: Activation of the mTOR pathway in primary medullary
thyroid carcinoma and lymph node metastases. Clin Cancer Res.
18:3532–3540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Simbolo M, Mian C, Barollo S, Fassan M,
Mafficini A, Neves D, Scardoni M, Pennelli G, Rugge M, Pelizzo MR,
et al: High-throughput mutation profiling improves diagnostic
stratification of sporadic medullary thyroid carcinomas. Virchows
Arch. 465:73–78. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Puppin C, Durante C, Sponziello M,
Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A,
Lacroix L, et al: Overexpression of genes involved in miRNA
biogenesis in medullary thyroid carcinomas with RET mutation.
Endocrine. 47:528–536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rapa I, Saggiorato E, Giachino D,
Palestini N, Orlandi F, Papotti M and Volante M: Mammalian target
of rapamycin pathway activation is associated to RET mutation
status in medullary thyroid carcinoma. J Clin Endocrinol Metab.
96:2146–2153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berrocal A, Cabañas L, Espinosa E,
Fernández-de-Misa R, Martín-Algarra S, Martínez-Cedres JC,
Ríos-Buceta L and Rodríguez-Peralto JL: Melanoma: Diagnosis,
staging and treatment. Consensus group recommendations. Adv Ther.
31:945–960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Muscarella P, Bloomston M, Brewer AR,
Mahajan A, Frankel WL, Ellison EC, Farrar WB, Weghorst CM and Li J:
Expression of the p16INK4A/Cdkn2a gene is prevalently downregulated
in human pheochromocytoma tumor specimens. Gene Expr. 14:207–216.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Güran S and Tali ET: p53 and p16INK4A
mutations during the progression of glomus tumor. Pathol Oncol Res.
5:41–45. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nikiforova MN, Kimura ET, Gandhi M,
Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G,
Fusco A, et al: BRAF mutations in thyroid tumors are restricted to
papillary carcinomas and anaplastic or poorly differentiated
carcinomas arising from papillary carcinomas. J Clin Endocrinol
Metab. 88:5399–5404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goutas N, Vlachodimitropoulos D, Bouka M,
Lazaris AC, Nasioulas G and Gazouli M: BRAF and K-RAS mutation in a
Greek papillary and medullary thyroid carcinoma cohort. Anticancer
Res. 28:305–308. 2008.PubMed/NCBI
|
|
15
|
Schulten HJ, Al-Maghrabi J, Al-Ghamdi K,
Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari
M and Al-Qahtani M: Mutational screening of RET, HRAS, KRAS, NRAS,
BRAF, AKT1 and CTNNB1 in medullary thyroid carcinoma. Anticancer
Res. 31:4179–4183. 2011.PubMed/NCBI
|
|
16
|
Boichard A, Croux L, Al Ghuzlan A, Broutin
S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM and Lacroix L:
Somatic RAS mutations occur in a large proportion of sporadic
RET-negative medullary thyroid carcinomas and extend to a
previously unidentified exon. J Clin Endocrinol Metab.
97:E2031–E2035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sauroja I, Smeds J, Vlaykova T, Kumar R,
Talve L, Hahka-Kemppinen M, Punnonen K, Jansèn CT, Hemminki K and
Pyrhönen S: Analysis of G(1)/S checkpoint regulators in metastatic
melanoma. Genes Chromosomes Cancer. 28:404–414. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pasquali D, Circelli L, Faggiano A,
Pancione M, Renzullo A, Elisei R, Romei C, Accardo G, Coppola VR,
De Palma M, et al: CDKN1B V109G polymorphism a new prognostic
factor in sporadic medullary thyroid carcinoma. Eur J Endocrinol.
164:397–404. 2011. View Article : Google Scholar
|
|
19
|
Tian Q, Frierson HF Jr, Krystal GW and
Moskaluk CA: Activating c-kit gene mutations in human germ cell
tumors. Am J Pathol. 154:1643–1647. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Samuels Y and Ericson K: Oncogenic PI3K
and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar
|
|
21
|
Kizys MM, Cardoso MG, Lindsey SC, Harada
MY, Soares FA, Melo MC, Montoya MZ, Kasamatsu TS, Kunii IS,
Giannocco G, et al: Optimizing nucleic acid extraction from thyroid
fine-needle aspiration cells in stained slides,
formalin-fixed/paraffin-embedded tissues and long-term stored blood
samples. Arq Bras Endocrinol Metabol. 56:618–626. 2012. View Article : Google Scholar
|
|
22
|
Venselaar H, Te Beek TA, Kuipers RK,
Hekkelman ML and Vriend G: Protein structure analysis of mutations
causing inheritable diseases. An e-Science approach with life
scientist friendly interfaces. BMC Bioinformatics. 11:5482010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee PH and Shatkay H: F-SNP:
Computationally predicted functional SNPs for disease association
studies. Nucleic Acids Res. 36(Database issue): D820–D824. 2008.
View Article : Google Scholar :
|
|
24
|
Edge SE, Byrd DR, Carducci MA, Compton CC,
Fritz AG, Greene F and Trotti A: AJCC Cancer Staging Manual.
Springer-Verlag; New York: 2009
|
|
25
|
Lindsey SC, Kunii IS, Germano-Neto F,
Sittoni MY, Camacho CP, Valente FO, Yang JH, Signorini PS, Delcelo
R, Cerutti JM, et al: Extended RET gene analysis in patients with
apparently sporadic medullary thyroid cancer: Clinical benefits and
cost. Horm Cancer. 3:181–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kumar R, Smeds J, Berggren P, Straume O,
Rozell BL, Akslen LA and Hemminki K: A single nucleotide
polymorphism in the 3′untranslated region of the CDKN2A gene is
common in sporadic primary melanomas but mutations in the CDKN2B,
CDKN2C, CDK4 and p53 genes are rare. Int J Cancer. 95:388–393.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chatterjee S and Pal JK: Role of 5′- and
3′-untranslated regions of mRNAs in human diseases. Biol Cell.
101:251–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sakano S, Berggren P, Kumar R, Steineck G,
Adolfsson J, Onelöv E, Hemminki K and Larsson P: Clinical course of
bladder neoplasms and single nucleotide polymorphisms in the CDKN2A
gene. Int J Cancer. 104:98–103. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Geddert H, Kiel S, Zotz RB, Zhang J,
Willers R, Gabbert HE and Sarbia M: Polymorphism of p16 INK4A and
cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J
Cancer Res Clin Oncol. 131:803–808. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chansaenroj J, Theamboonlers A,
Junyangdikul P, Swangvaree S, Karalak A, Chinchai T and Poovorawan
Y: Polymorphisms in TP53 (rs1042522), p16 (rs11515 and rs3088440)
and NQO1 (rs1800566) genes in Thai cervical cancer patients with
HPV 16 infection. Asian Pac J Cancer Prev. 14:341–346. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Straume O, Smeds J, Kumar R, Hemminki K
and Akslen LA: Significant impact of promoter hypermethylation and
the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the
vertical growth phase. Am J Pathol. 161:229–237. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Boonstra JJ, van Marion R, Tilanus HW and
Dinjens WN: Functional polymorphisms associated with disease-free
survival in resected carcinoma of the esophagus. J Gastrointest
Surg. 15:48–56. 2011. View Article : Google Scholar :
|
|
33
|
Pinheiro UB, de Carvalho Fraga CA, Mendes
DC, Marques-Silva L, Farias LC, de Souza MG, Soares MB, Jones KM,
Santos SH, de Paula AM, et al: p16 (CDKN2A) SNP rs11515 was not
associated with head and neck carcinoma. Tumour Biol. 35:6113–6118.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin L, Xu L, Song X, Wei Q, Sturgis EM and
Li G: Genetic variation in MDM2 and p14ARF and susceptibility to
salivary gland carcinoma. PloS One. 7:e493612012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Polakova V, Pardini B, Naccarati A, Landi
S, Slyskova J, Novotny J, Vodickova L, Bermejo JL, Hanova M,
Smerhovsky Z, et al: Genotype and haplotype analysis of cell cycle
genes in sporadic colorectal cancer in the czech republic. Hum
Mutat. 30:661–668. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Royds JA, Al Nadaf S, Wiles AK, Chen YJ,
Ahn A, Shaw A, Bowie S, Lam F, Baguley BC, Braithwaite AW, et al:
The CDKN2A G500 allele is more frequent in GBM patients with no
defined telomere maintenance mechanism tumors and is associated
with poorer survival. PloS One. 6:e267372011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thakur N, Hussain S, Nasare V, Das BC,
Basir SF and Bharadwaj M: Association analysis of p16 (CDKN2A) and
RB1 polymorphisms with susceptibility to cervical cancer in Indian
population. Mol Biol Rep. 39:407–414. 2012. View Article : Google Scholar
|
|
38
|
Zhang Y, Sturgis EM, Zafereo ME, Wei Q and
Li G: p14ARF genetic polymorphisms and susceptibility to second
primary malignancy in patients with index squamous cell carcinoma
of the head and neck. Cancer. 117:1227–1235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang F, Xu L, Wei Q, Song X, Sturgis EM
and Li G: Significance of MDM2 and P14 ARF polymorphisms in
susceptibility to differentiated thyroid carcinoma. Surgery.
153:711–717. 2013. View Article : Google Scholar :
|
|
40
|
De Giorgi V, Savarese I, D'Errico A, Gori
A, Papi F, Colombino M, Cristina Sini M, Stanganelli I, Palmieri G
and Massi D: CDKN2A mutations could influence the dermoscopic
pattern of presentation of multiple primary melanoma: A clinical
dermoscopic genetic study. J Eur Acad Dermatol Venereol.
29:574–580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song X, Sturgis EM, Huang Z, Li X, Li C,
Wei Q and Li G: Potentially functional variants of p14ARF are
associated with HPV-positive oropharyngeal cancer patients and
survival after definitive chemoradiotherapy. Carcinogenesis.
35:62–68. 2014. View Article : Google Scholar
|
|
42
|
Stenman G, Andersson MK and Andrén Y: New
tricks from an old oncogene: Gene fusion and copy number
alterations of MYB in human cancer. Cell Cycle. 9:2986–2995. 2010.
View Article : Google Scholar : PubMed/NCBI
|
